Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
Anne HuAshwin N Ananthakrishnan

Abstract

Patients with Crohn's disease (CD) or ulcerative colitis (UC) often receive combination therapy with an immunomodulator and tumor necrosis factor antagonists, especially infliximab. However, the benefits of combination therapy with vedolizumab and ustekinumab are unclear. We performed a retrospective study of patients with CD or UC initiating vedolizumab or ustekinumab therapy at Massachusetts General Hospital (USA), Alberta Health Sciences (Canada), or Nancy University Hospital (France) with at least 1 year of follow up. The primary outcome was clinical remission or response at week 14, based on the Harvey Bradshaw index for CD or simple clinical colitis index or partial Mayo score for UC. We separately examined week 30 and week 54 clinical outcomes, endoscopic response, and durability of therapy using multivariable regression models and adjusting for relevant confounders. Our study included 549 patients (263 with UC, 286 with CD) receiving maintenance therapy with vedolizumab and 363 patients (4 with UC, 359 with CD) receiving maintenance therapy with ustekinumab with 1 year of follow up. The mean disease duration was 13-15 years. One-hundred thirty-one patients receiving vedolizumab (23.9%; 78 receiving thiopurine, 53 receiv...Continue Reading

References

Jun 6, 2002·Lancet·Stephen B HanauerUNKNOWN ACCENT I Study Group
Dec 13, 2005·The New England Journal of Medicine·Paul RutgeertsJean Frédéric Colombel
Jul 20, 2007·The New England Journal of Medicine·William J SandbornUNKNOWN PRECISE 1 Study Investigators
Jul 20, 2007·The New England Journal of Medicine·Stefan SchreiberUNKNOWN PRECISE 2 Study Investigators
Jul 28, 2007·Clinical Pharmacokinetics·Ulrich KlotzMatthias Schwab
Apr 16, 2010·The New England Journal of Medicine·Jean Frédéric ColombelUNKNOWN SONIC Study Group
Oct 19, 2012·The New England Journal of Medicine·William J SandbornUNKNOWN CERTIFI Study Group
Oct 30, 2012·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Shomron Ben-HorinYehuda Chowers
Jun 6, 2013·Gastroenterology·William J SandbornUNKNOWN PURSUIT-SC Study Group
Jun 19, 2013·Gastroenterology·William J SandbornUNKNOWN PURSUIT-Maintenance Study Group
Aug 24, 2013·The New England Journal of Medicine·Brian G FeaganUNKNOWN GEMINI 1 Study Group
Aug 24, 2013·The New England Journal of Medicine·William J SandbornUNKNOWN GEMINI 2 Study Group
Sep 18, 2014·Inflammatory Bowel Diseases·Tamara van SchaikAndrea E van der Meulen-de Jong
Jul 5, 2015·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Jennifer L JonesCorey A Siegel
Aug 26, 2015·The American Journal of Gastroenterology·L Peyrin-BirouletJ-F Colombel
Jan 12, 2016·Inflammatory Bowel Diseases·Kimberly A HarrisDavid A Schwartz
Dec 14, 2016·The New England Journal of Medicine·Brian G FeaganUNKNOWN UNITI–IM-UNITI Study Group
Apr 4, 2017·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Robert BattatWaqqas Afif
May 20, 2017·Clinical Pharmacokinetics·Maria RosarioIrving Fox
Dec 11, 2017·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Bella UngarShomron Ben-Horin
Feb 8, 2018·Gastroenterology·Omoniyi J AdedokunWilliam J Sandborn
Mar 22, 2018·Inflammatory Bowel Diseases·Britt ChristensenDavid T Rubin
Apr 16, 2018·Gastroenterology·Julien KirchgesnerRosemary Dray-Spira
Aug 1, 2018·Alimentary Pharmacology & Therapeutics·Paulo G KotzeRemo Panaccione
Mar 3, 2019·The Lancet. Gastroenterology & Hepatology·Nicholas A KennedyUNKNOWN UK Inflammatory Bowel Disease Pharmacogenetics Study Group
Jun 21, 2019·Journal of Crohn's & Colitis·Vince B C BiemansUNKNOWN Dutch Initiative on Crohn and Colitis (ICC)

❮ Previous
Next ❯

Citations

Mar 19, 2021·Current Opinion in Gastroenterology·Bincy Abraham, Kerri Glassner
Jun 3, 2021·Biomedicines·Vipul YadavAbdul W Basit
Jun 21, 2021·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Blake Jones
Jun 16, 2021·Journal of Internal Medicine·Klaus R Herrlinger, Eduard F Stange
Nov 29, 2020·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Prasanta Debnath, Pravin Rathi
Dec 6, 2020·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Britt Christensen, David T Rubin

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.